From the biological point of view, at the time of TKI withdrawal, the majority of CML patients (56%) still harbored a low yet detectable amount of CD26+LSCs in their peripheral blood, without any significant difference according to previous TKI treatment. Here, DPP4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.